Nvidia is one of BofA's top 'rebound' stock picks. Here are the others.
By Emily Bary
Nvidia's stock is one of the S&P 500's best performers in Monday action as BofA outlines why a 'rebound' scenario makes sense for the semiconductor sector
If the semiconductor sector bounces back, Nvidia Corp.'s stock looks like a good play, according to BofA analyst Vivek Arya.
He assumes a sector rebound, likely in the fourth quarter of this year, as seasonal headwinds could fade by then. Investors await Nvidia's (NVDA) earnings report later this month, but September has traditionally been the worst month for the PHLX Semiconductor Index SOX, Arya said, which is why some patience may be required.
The good news is that the calendar fourth and first quarters typically are much better for chip stocks, a dynamic that is helping fuel Arya's prediction for a rebound. In such a situation, shares of Nvidia, Broadcom Inc. (AVGO) and KLA Corp. (KLAC) are his top picks, as those companies are "the most profitable vendors in their respective end markets."
Nvidia shares are up 5.8% and are among the leading S&P 500 gainers in Monday action. KLA shares are up 1.6% and Broadcom shares are up 1.1%.
Don't miss: Only AMD's stock has achieved this feat since 1999, but Nvidia's could follow
Arya noted in a Monday report that the semiconductor "upcycle" has only lasted four quarters thus far, with the PHLX Semiconductor Index up 28% in that time. On a historical basis, such cycles have gone on for 10 quarters on average and brought a 67% move higher for the index.
Investors have been worried about whether artificial intelligence will deliver the necessary return on heavy investment spending, and Arya said those concerns are "valid but premature and inconclusive."
See also: Intel CEO bought stock after selloff. That's not the signal you may think it is.
For one, AI spending "is as much defensive (protecting search, social or e-commerce dominance) as it is offensive (new revenue streams)," he wrote. Additionally, enterprise and sovereign adoption of AI is still in the early stages, and Nvidia's new Blackwell chip that's "best suited for AI" has yet to start shipping.
"In other words, waiting for large cloud providers to confess about low AI [return on investment] is a wasted cause" - at least until 2026, Arya wrote. And he argued that while semiconductor stocks exposed to cloud trends "can often get crowded and volatile," business dynamics elsewhere in the semiconductor sector are murkier.
Although Arya's model calls for a rebound scenario, he also identified some names that could work against a more "recessionary" backdrop. Those include Cadence Design Systems Inc. (CDNS), Synopsys Inc. (SNPS) and Broadcom, which have a history of outperformance.
Meanwhile, in the case of a "resurgence scenario and potential high-beta rally," he thinks shares of Arm Holdings PLC (ARM), Micron Technology Inc. (MU) and ON Semiconductor Corp. (ON) could be standouts.
Read: Micron's stock is down 30% in a month. Why Citi says to 'double down' and buy.
-Emily Bary
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-12-24 1042ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks